SI1731912T1 - Postopek izbire peptida - Google Patents

Postopek izbire peptida

Info

Publication number
SI1731912T1
SI1731912T1 SI200131032T SI200131032T SI1731912T1 SI 1731912 T1 SI1731912 T1 SI 1731912T1 SI 200131032 T SI200131032 T SI 200131032T SI 200131032 T SI200131032 T SI 200131032T SI 1731912 T1 SI1731912 T1 SI 1731912T1
Authority
SI
Slovenia
Prior art keywords
selection method
peptide
peptide selection
mbp
peptides
Prior art date
Application number
SI200131032T
Other languages
English (en)
Inventor
David Cameron University Of Bristol Wraith
Stephen Mark University Of Edinburgh Anderton
Graziella University of Bristol Mazza
Mary Ponsford
Heather Barbara University Of Bristol Streeter
Original Assignee
Apitope Technology (Bristol) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1731912(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0020618A external-priority patent/GB0020618D0/en
Priority claimed from GB0114547A external-priority patent/GB0114547D0/en
Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited
Publication of SI1731912T1 publication Critical patent/SI1731912T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
SI200131032T 2000-08-21 2001-08-17 Postopek izbire peptida SI1731912T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020618A GB0020618D0 (en) 2000-08-21 2000-08-21 Peptide selection method
GB0114547A GB0114547D0 (en) 2001-06-14 2001-06-14 Peptide selection method
EP06014901.0A EP1731912B1 (en) 2000-08-21 2001-08-17 Peptide selection method

Publications (1)

Publication Number Publication Date
SI1731912T1 true SI1731912T1 (sl) 2014-05-30

Family

ID=26244875

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200130860T SI1311542T1 (sl) 2000-08-21 2001-08-17 Tolerogenski peptidi
SI200131032T SI1731912T1 (sl) 2000-08-21 2001-08-17 Postopek izbire peptida
SI200130983T SI1918298T1 (sl) 2000-08-21 2001-08-17 Peptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200130860T SI1311542T1 (sl) 2000-08-21 2001-08-17 Tolerogenski peptidi

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200130983T SI1918298T1 (sl) 2000-08-21 2001-08-17 Peptid

Country Status (25)

Country Link
US (4) US20030191063A1 (sl)
EP (3) EP1918298B1 (sl)
JP (1) JP5431628B2 (sl)
KR (1) KR20030062321A (sl)
CN (4) CN102784385B (sl)
AT (2) ATE483729T1 (sl)
AU (2) AU2001278637B2 (sl)
BR (2) BRPI0113400B1 (sl)
CA (1) CA2420949C (sl)
CY (3) CY1108558T1 (sl)
CZ (1) CZ307202B6 (sl)
DE (2) DE60134862D1 (sl)
DK (3) DK1918298T3 (sl)
ES (3) ES2310558T3 (sl)
HK (3) HK1052359B (sl)
HU (3) HU229489B1 (sl)
IL (1) IL154089A0 (sl)
MX (1) MXPA03001606A (sl)
NO (2) NO330535B1 (sl)
NZ (1) NZ523841A (sl)
PH (1) PH12013500208B1 (sl)
PL (4) PL215187B1 (sl)
PT (3) PT1311542E (sl)
SI (3) SI1311542T1 (sl)
WO (1) WO2002016410A2 (sl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0113400B1 (pt) 2000-08-21 2018-05-15 Apitope Technology Bristol Método para seleção de peptídeo
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US20100003228A1 (en) * 2006-05-05 2010-01-07 Willimas Jim C T-cell vaccine
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US9340580B2 (en) 2007-08-15 2016-05-17 Circassia Limited Peptide with multiple epitopes
CN101848725B (zh) * 2007-10-31 2013-05-22 艾匹托普技术(布里斯托尔)有限公司 组合物
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
ITMI20080508A1 (it) * 2008-03-27 2009-09-28 Istituto Nazionale Di Genetica Molecolare Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
WO2010127186A1 (en) 2009-04-30 2010-11-04 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
ES2566230T3 (es) 2009-10-12 2016-04-11 Lifebio Laboratories Llc Composición para el tratamiento de la esclerosis múltiple
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
DK2556171T3 (en) 2010-04-05 2015-12-14 Prognosys Biosciences Inc Spatially CODED BIOLOGICAL ASSAYS
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
KR200457779Y1 (ko) * 2010-06-23 2012-01-06 이준혁 샤프펜슬
EP3150750B1 (en) 2011-04-08 2018-12-26 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
PL397623A1 (pl) * 2011-12-30 2013-07-08 Napco S. Ar.L. Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
SG11201503657UA (en) 2012-11-12 2015-06-29 Apitope Int Nv Peptides
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2972366B1 (en) * 2013-03-15 2020-06-17 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
CN111662960B (zh) 2013-06-25 2024-04-12 普罗格诺西斯生物科学公司 采用微流控装置的空间编码生物分析
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
MX2017008505A (es) * 2014-12-24 2018-03-07 Apitope Int Nv Composicion.
DK3901281T3 (da) 2015-04-10 2023-01-23 Spatial Transcriptomics Ab Rumligt adskilt, multipleks nukleinsyreanalyse af biologiske prøver
EP3565585A1 (en) * 2017-01-04 2019-11-13 Apitope International NV Therapeutic method using tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
JP7174492B2 (ja) * 2017-01-04 2022-11-17 ウォルグ ファーマシューティカルズ （ハンジョウ） カンパニー，リミテッド Ｓ－アレスチンペプチドおよびその治療的使用
US10174122B2 (en) 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
RU2761617C2 (ru) * 2019-10-04 2021-12-13 Жаудат Гафурович Умеров Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
GB201919222D0 (en) 2019-12-23 2020-02-05 Apitope Int Nv Composition
TR201922305A2 (tr) * 2019-12-30 2021-07-26 T C Erciyes Ueniversitesi Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
WO2021144478A2 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327162C (en) 1987-04-09 1994-02-22 Board Of Trustees Of The Leland Stanford Junior University (The) Method for prophylactically treating an individual for an autoimmune disease
EP0666080B1 (en) 1987-06-24 2004-01-21 Brigham & Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5593698A (en) * 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en) * 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
CZ329596A3 (en) * 1994-05-10 1997-05-14 Immulogic Pharma Corp Preparation for treating scattered sclerosis
AU7242994A (en) 1994-05-20 1995-12-18 United States Of America, As Represented By The Secretary Of The Army, The Model for testing immunogenicity of peptides
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
EP0825870A4 (en) * 1995-04-20 2002-09-25 Brigham & Womens Hospital MODULATION OF CYTOKINIC SEQUENCES OF SELF-REACTIVE T HUMAN CELL CLONES
AU738649B2 (en) * 1996-04-26 2001-09-20 Rijksuniversiteit Te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
EP0849275A1 (en) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
EP1085892A4 (en) 1998-06-12 2002-07-17 Sloan Kettering Inst Cancer VACCINE STRATEGY FOR THE PREVENTION AND TREATMENT OF CANCER
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
BRPI0113400B1 (pt) * 2000-08-21 2018-05-15 Apitope Technology Bristol Método para seleção de peptídeo
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US8314290B2 (en) 2004-12-21 2012-11-20 Monsanto Technology Llc Temporal regulation of gene expression by MicroRNAs
CN101848725B (zh) 2007-10-31 2013-05-22 艾匹托普技术(布里斯托尔)有限公司 组合物
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides

Also Published As

Publication number Publication date
NO337988B1 (no) 2016-07-18
CN102764425A (zh) 2012-11-07
CZ307202B6 (cs) 2018-03-21
PL399138A1 (pl) 2012-07-30
WO2002016410A2 (en) 2002-02-28
PL213585B1 (pl) 2013-03-29
EP1918298A2 (en) 2008-05-07
HUP0300814A3 (en) 2005-11-28
NO20030790L (no) 2003-04-22
EP1731912A2 (en) 2006-12-13
HK1178793A1 (en) 2013-09-19
AU7863701A (en) 2002-03-04
PL217929B1 (pl) 2014-09-30
NO330535B1 (no) 2011-05-09
JP5431628B2 (ja) 2014-03-05
PT1731912E (pt) 2013-12-17
EP1731912B1 (en) 2013-09-25
US20030191063A1 (en) 2003-10-09
NO20030790D0 (no) 2003-02-19
HU229377B1 (hu) 2013-11-28
DE60143234D1 (de) 2010-11-18
PH12013500208A1 (en) 2015-04-20
BRPI0113400B1 (pt) 2018-05-15
AU2001278637B2 (en) 2006-05-25
ES2310558T3 (es) 2009-01-16
HU230233B1 (hu) 2015-10-28
NZ523841A (en) 2004-07-30
ES2439899T3 (es) 2014-01-27
NO20101441L (no) 2003-04-22
EP1918298A3 (en) 2008-05-28
HK1052359B (zh) 2008-11-14
CN101633689B (zh) 2013-09-04
WO2002016410A3 (en) 2002-09-12
CA2420949C (en) 2012-01-03
ES2353347T3 (es) 2011-03-01
HK1052359A1 (en) 2003-09-11
JP2004506921A (ja) 2004-03-04
ATE483729T1 (de) 2010-10-15
BR0113400A (pt) 2003-07-08
PH12013500208B1 (en) 2015-04-20
CN1469883A (zh) 2004-01-21
HK1178437A1 (en) 2013-09-13
PL399137A1 (pl) 2012-07-30
PL215187B1 (pl) 2013-11-29
US8343500B2 (en) 2013-01-01
HUP0300814A2 (hu) 2003-10-28
EP1918298B1 (en) 2010-10-06
HU229489B1 (hu) 2014-01-28
US8961986B2 (en) 2015-02-24
EP1731912A3 (en) 2006-12-27
CN102784385B (zh) 2015-11-25
SI1918298T1 (sl) 2011-01-31
MXPA03001606A (es) 2004-11-01
PT1311542E (pt) 2008-10-03
DK1918298T3 (da) 2010-11-29
US20130156798A1 (en) 2013-06-20
EP1311542A2 (en) 2003-05-21
CY1114808T1 (el) 2016-12-14
CN102764425B (zh) 2015-11-25
US20180311328A1 (en) 2018-11-01
CN102784385A (zh) 2012-11-21
DK1731912T3 (da) 2014-01-06
CY1111079T1 (el) 2015-06-11
DK1311542T3 (da) 2008-11-10
CY1108558T1 (el) 2014-04-09
US20080200368A1 (en) 2008-08-21
PL215145B1 (pl) 2013-10-31
PL364048A1 (en) 2004-12-13
KR20030062321A (ko) 2003-07-23
PT1918298E (pt) 2010-12-09
DE60134862D1 (de) 2008-08-28
IL154089A0 (en) 2003-07-31
EP1311542B1 (en) 2008-07-16
ATE401343T1 (de) 2008-08-15
CN101633689A (zh) 2010-01-27
SI1311542T1 (sl) 2009-02-28
CA2420949A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
HK1178793A1 (en) Peptide selection method
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
AU2002229510A1 (en) Combined use of factor vii polypeptides and factor viii polypeptides
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
NZ515936A (en) Antigenic Neisserial peptides
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
WO2004069204A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2004069208A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2004069205A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO1997039020A3 (en) Antigenic sequences of a sperm protein and immunocontraceptive methods